Sort   by:  
 Page size 
UnknownNew targetable oncogenes in non-small-cell lung cancer.
Not available
S-EPMC3589703 | biostudies-literature
TranscriptomicsAberrant ERK signaling causes resistance to EGFR kinase inhibitors
The clinical efficacy of EGFR kinase inhibitors is limited by the development of drug resistance. The irreversible EGFR kinase inhibitor WZ4002 is effective against the most common mechanism of drug resistance mediated by the EGFR T790M mutation. Here we show that in multiple complementary models ha...
ORGANISM(S): Homo sapiens 
2012-10-01 | E-GEOD-37699 | biostudies-arrayexpress
TranscriptomicsActivation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab
HCC827 cells were grown in gradually increasing concentrations of cetuximab beginning at 0.1 ug/ml. Drug concentrations were slowly increased until the resistant cells were able to proliferate in 100 ug/ml of cetuximab. Individual clones of cetuximab resistant (CR; CR1 to CR4) cells were isolated an...
ORGANISM(S): Homo sapiens 
2011-11-23 | E-GEOD-30255 | biostudies-arrayexpress
UnknownRandomized phase II trial of erlotinib alone or with carboplatin and paclitaxel in patients who were never or light former smokers with advanced lung adenocarcinoma: CALGB 30406 trial.
Not available
S-EPMC3397694 | biostudies-literature
UnknownRandomized phase II study of erlotinib in combination with placebo or R1507, a monoclonal antibody to insulin-like growth factor-1 receptor, for advanced-stage non-small-cell lung cancer.
Not available
S-EPMC5320944 | biostudies-literature
UnknownMulticenter, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin plus bevacizumab or placebo in patients with malignant mesothelioma.
Not available
S-EPMC3397785 | biostudies-literature
UnknownPooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.
Not available
S-EPMC6075828 | biostudies-literature
UnknownPhase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH).
Not available
S-EPMC5562171 | biostudies-literature
GenomicsWhole Genome and Exon Capture Sequencing of Bladder Cancers

One primary bladder cancer and paired peripheral blood sample were subjected to whole genome sequencing on an Illumina HiSeq 2000 platform. This technology was utilized to investigate the genetic basis of a durable remission of metastatic bladder cancer in a patient treated with everolimus, a dru...

phs000535.v1.p1 | EGA
Sort   by:  
 Page size